In recognizing International Day of Women and Girls in Science this week, we're highlighting our VP of Portfolio and Program Management, Pam Howland. Pam shared with us her mentors, interest in science, and advice for girls pursuing #STEM fields. Read her responses below. #IDWGS #WomenInSTEM #WomenInScience #RepresentationMatters #TeamBolt
关于我们
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody? Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.
- 网站
-
https://boltbio.com/
Bolt Biotherapeutics, Inc. 的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- REDWOOD CITY，California
- 类型
- 上市公司
- 创立
- 2015
地点
-
主要
获取路线
900 CHESAPEAKE DRIVE
US，California，REDWOOD CITY，94063
Bolt Biotherapeutics, Inc. 员工
动态
-
Today, with our collaborators at Toray Industries, Inc., we announced that the target of our worldwide co-development collaboration is Caprin-1, a novel cancer target discovered by Toray. This co-developed Boltbody? #ISAC will be applicable to multiple solid tumor types. Learn more about the?target and our collaboration:?https://bit.ly/40MBK92
-
-
From our #TeamBolt family to yours,?we’re wishing you a happy, healthy, and safe holiday season! Thank you for following our story as we progress our mission to leverage the immune system for a better way to treat cancer. Here's to an exciting 2025!
-
-
Earlier this month, our Senior Director and Program Team Lead, Shelley Ackerman, Ph.D., presented the advantages of next-generation #ISACs at World ADC Event Series San Diego conference! #TeamBolt #CancerResearch #Immunooncology
-
-
Today #BoltBio reported financial results for the third quarter and provided corporate updates.?Learn more: https://bit.ly/4fqJ7sQ
-
-
Our team is attending the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting and will present updated preclinical activity of BDC-4182 and key learnings from Phase 1 dose-escalation trial of BDC-1001. Learn more: https://bit.ly/4enqLrc #SITC24 #ImmunoOncology #CancerResearch
-
-
Our next-generation Boltbody? #ISAC program, BDC-4182, consists of a Claudin 18.2-targeting antibody that is covalently attached to a toll-like receptor (TLR) 7/8 agonist via a non-cleavable linker.??? ?? TLR7 and TLR8 are located within immune cells and play a crucial role in the body’s immune system by helping it to recognize and eliminate pathogens. TLR7 and TLR8 are expressed in a variety of immune cells capable of killing tumor cells and stimulating T cell-mediated anti-tumor responses, including:? ? ● Plasmacytoid dendritic cells (TLR7)?? ● Conventional dendritic cells (TLR7 & TLR8)?? ● Monocytes (TLR7 & TLR8)?? ● Macrophages (TLR7 & TLR8)?? ● Neutrophils (TLR8)?? ?? In pre-clinical models, BDC-4182 has demonstrated potent anti-tumor activity,?induction of T cell-dependent immunological memory, and an acceptable safety profile.?? Learn more about our science: https://bit.ly/3VunkZR??
-